Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in revenues and adjusted earnings that is unchanged from the year-ago period.
Third-quarter profit, adjusted for one-off items, remained unchanged at $4.77 per share. Meanwhile, net profit more than doubled year-over-year to $1.13 billion or $7.84 per share.
Revenues decreased 10% annually to $2.51 billion during the three-month period, mainly reflecting an 11% fall in sales at the core product segment.
“We are excited about the topline results of the Clarity AD trial for lecanemab and believe this potential new therapy could provide a meaningful benefit for Alzheimer’s patients. We also continue to make progress toward delivering new impactful therapies for patients suffering from depression and SOD1 ALS, with important upcoming regulatory milestones,” said Biogen’s CEO Michel Vounatsos.
Spotify ended 2025 on a strong note, reporting steady revenue growth and a sharp jump…
Jerash Holdings (US), Inc. (NASDAQ: JRSH) reported significantly improved financial results for the fiscal 2026…
Shares of Prospect Capital Corporation (PSEC) traded mixed to slightly positive in early trading on…
Waters Corporation (WAT) shares dropped 14.49% to $326.04 in early trading on Tuesday after the…
Universal Corp. (UVV) shares fell 10.72% to $51.62 in Tuesday trading after the global agriproducts…
Upwork Inc (UPWK) shares fell 4.76% to $17.89 in early trading on Tuesday after the…